ORIGINAL RESEARCH article
Front. Cell Dev. Biol.
Sec. Molecular and Cellular Pathology
Volume 13 - 2025 | doi: 10.3389/fcell.2025.1635878
This article is part of the Research TopicAdvancements in Understanding and Managing Preeclampsia: Exploring Molecular Mechanisms, Biomarkers, and Clinical ImplicationsView all 9 articles
Molecular Signatures of Preeclampsia Subtypes Determined Through Integrated Weighted Gene Co-expression Network Analysis and Differential Gene Expression Analysis of Placental Transcriptomics
Provisionally accepted- 1School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Queensland, Australia
- 2Women-Newborn-Children-Services, Gold Coast University Hospital, Gold Coast, Queensland, Australia
- 3School of Medicine and Dentistry, Griffith University, Gold Coast, Queensland, Australia
- 4Maternal Fetal Medicine Unit, Women-Newborn-Children Services, Gold Coast University Hospital, Gold Coast, Queensland, Australia
- 5School of Health, University of the Sunshine Coast, Sunshine Coast, Queensland, Australia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Preeclampsia (PE) is a multisystemic pregnancy syndrome that presents in different clinical subtypes. While placental dysfunction is a critical feature of PE, its contribution to different PE subtypes remains unclear. This study aims to use integrated bioinformatics analysis of placental transcriptomics to investigate subtype-specific molecular mechanisms associated with PE.Methods: A systematic search of the Gene Expression Omnibus (GEO) repository identified two datasets (GSE234729, n=123; GSE75010, n=157) for integrated Weighted Gene Co-expression Network Analysis (WGCNA) and differential gene expression analysis. We constructed co-expression networks and identified gene modules correlated with three PE subtypes (severe, early-onset and late-onset). Differential gene expression analysis was conducted using the "limma" R package. Differentially expressed genes (DEGs) overlapping with PE subtype-correlated WGCNA modules underwent Gene Ontology (GO) enrichment analysis. Consistently dysregulated genes were validated in an additional external dataset (GSE25906) and RT-PCR analysis of placental samples from 21 PE cases and 21 uncomplicated controls.Results: We identified distinct molecular signatures associated with each PE subtype. The green gene module was positively correlated with severe PE (r = 0.63, p = 4e-15), containing 179 DEGs primarily involved in lipid metabolism and hypoxia response processes. Early-onset PE had two highly significant gene modules: the yellow module (r = 0.73, p = 4e-15) with 112 DEGs enriched in biological processes related to gonadotrophin secretion and lipid storage, and the black module (r = -0.55, p = 5e-08) with 47 DEGs significantly enriched in chronic inflammation responses. Late-onset PE showed moderate correlation with the ivory module (r = 0.46, p = 5e-05), containing 23 DEGs enriched in p38MAPK stress-response signalling. Cross-subtype analysis identified 20 consistently dysregulated genes across three PE subtypes, with four upregulated genes (LEP, FSTL3, HTRA4, and HK2) confirmed in the external dataset GSE25906. However, RT-PCR validation showed only moderate upregulation without statistical significance.Conclusion: Though placental dysfunction occurs across all subtypes with a core set of upregulated genes, variation exits in placental gene expression patterns among PE subtypes. Severe and early-onset PE exhibit large molecular perturbations, while late-onset PE presents more subtle alterations. Aberrant placental lipid storage may contribute to disease severity and early manifestation.
Keywords: Preeclampsia, subtype, molecular, Transcriptomics, Placenta
Received: 27 May 2025; Accepted: 15 Jul 2025.
Copyright: © 2025 Han, Holland, Da Silva Costa and Perkins. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Olivia Holland, School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Queensland, Australia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.